Travere Therapeutics: Tricky Outlook Gives Me Pause For Thought – Downgrade Source link Edmund Ingham
Travere Therapeutics: Tricky Outlook Gives Me Pause For Thought – Downgrade Read More »
Gilead Sciences: 2025 Preview, A Buy Thanks To Thriving HIV Franchise Source link Edmund Ingham
Gilead Sciences: 2025 Preview, A Buy Thanks To Thriving HIV Franchise Read More »
This article was written by Follow Edmund Ingham is a biotech consultant. He has been covering biotech, healthcare, and pharma for over 5 years, and has put together detailed reports of over 1,000 companies. He leads the investing group Haggerston
This article was written by Follow Edmund Ingham is a biotech consultant. He has been covering biotech, healthcare, and pharma for over 5 years, and has put together detailed reports of over 1,000 companies. He leads the investing group Haggerston
Humacyte Stock: FDA Waiting Game, Bleeding Company Dry (NASDAQ:HUMA) Read More »
This article was written by Follow Edmund Ingham is a biotech consultant. He has been covering biotech, healthcare, and pharma for over 5 years, and has put together detailed reports of over 1,000 companies. He leads the investing group Haggerston
ImmunityBio: Despite Share Price & Funding Woes Muddy Path To Long-Term Success (IBRX) Read More »
This article was written by Follow Edmund Ingham is a biotech consultant. He has been covering biotech, healthcare, and pharma for over 5 years, and has put together detailed reports of over 1,000 companies. He leads the investing group Haggerston
Regeneron: Recent Bear Run May Be Justified – Pharma Faces A Testing 2025 (NASDAQ:REGN) Read More »
Bausch + Lomb And Bausch Health: Some Incremental Progress As We Wait For Sale News Source link Edmund Ingham
Bausch + Lomb And Bausch Health: Some Incremental Progress As We Wait For Sale News Read More »
MicroStockHub/iStock via Getty Images Investment Overview – Background To Recent Explosive Share Price Growth Foster City, California based Vaxcyte (NASDAQ:PCVX) completed its Initial Public Offering (IPO) in June 2020, raising $287.5m via the issuance of ~18m shares priced at $16
Vaxcyte: Stunning PCV Data Readout Suggests Vaccine Maker Is A Strong Buy (PCVX) Read More »
Toshe_O Investment Overview: Hims and Hers Stock Gains On Compounded GLP-1 agonist Drugs, When I last covered Hims & Hers Health (NYSE:HIMS) for Seeking Alpha in late May, the company’s stock had just jumped ~25% in value, to ~$18 per
